rss
J Clin Pathol 2004;57:177-182 doi:10.1136/jcp.2003.11270
  • Original article

A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia

  1. M Dinis-Ribeiro1,2,
  2. C Lopes3,
  3. A da Costa-Pereira2,
  4. M Guilherme3,
  5. J Barbosa3,
  6. H Lomba-Viana1,
  7. R Silva1,
  8. L Moreira-Dias1
  1. 1Department of Gastroenterology, Oncology Portuguese Institute Porto, 4200-072 Porto, Portugal
  2. 2Department of Biostatistics and Medical Informatic, Porto Faculty of Medicine, 4200-072 Porto, Portugal
  3. 3Department of Pathology, Oncology Portuguese Institute Porto and Porto Faculty of Medicine, 4200-072 Porto, Portugal
  1. Correspondence to:
 Dr M Dinis-Ribeiro
 Instituto Português de Oncologia ‘Francisco Gentil’, Serviço de Gastrenterologia, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal; mariomed.up.pt
  • Accepted 8 August 2003

Abstract

Aim: To devise a follow up model for patients with gastric cancer associated lesions, such as atrophic chronic gastritis (ACG) and intestinal metaplasia (IM).

Methods: Cohort study of 144 patients, followed for a minimum of one year, in whom at least two upper gastrointestinal endoscopic biopsies in flat gastric mucosa provided a diagnosis of ACG, IM, or low grade dysplasia (LGD).

Results: Of those diagnosed with ACG at first endoscopic biopsy (entry biopsy), 12% progressed to LGD in outcome biopsy, as did 8% of those with type I IM, 38% with type II or III IM, and 32% with LGD. Type of IM at entry independently predicted progression to LGD and cancer. Type II and III IM had a higher rate of progression to LGD than type I IM, which showed an indolent behaviour similar to ACG. Patients with type II or III IM were at higher risk for development of dysplasia, and 7% of patients with type III IM at first biopsy progressed to high grade dysplasia (HGD), whereas no cases of ACG or type I/II IM progressed to HGD during the first three years.

Conclusion: Patients with ACG or IM could possibly be allocated to different management schedules, based on differences in rate and proportion of progression to LGD or HGD. Less intensive follow up (two/three yearly with “serological evaluation” (pepsinogen)) may suit those with ACG or type I IM. Patients with type III IM may benefit from six to 12 monthly improved endoscopic examination (magnification chromoendoscopy).

Footnotes

  • Part of these results were presented as an oral communication at EUGW, Amsterdam, 2001, and published in an abstract in Gut (Gut2001;(suppl III):).

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.